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Abstract
Background: To analyze the presence of salivary Epstein-Barr virus (EBV) DNA in oral squamous cell carcinoma 
and potentially malignant oral disorders. 
Material and Methods: Three groups were studied: Group 1 (12 oral squamous cell carcinomas (OSCC)), Group 
2 (12 potentially malignant oral disorders (PMD)) and Group 3 (47 healthy controls). EBV DNA salivary analysis 
was performed by PCR.
Results: The highest percentage of positive salivary EBV DNA corresponded to the OSCC group (58.3%), followed 
by the PMD group (41.7%) and the controls (40.4%). The differences between groups were not statistically signifi-
cant, however (p>0.05). 
Conclusions: Salivary EBV DNA was more prevalent in OSCC than in PMD or the controls.
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Introduction
Epstein-Barr virus (EBV) is a very well known onco-
genic human herpes virus that has been implicated in 
several malignant tumors affecting epithelial cells and 
B lymphocytes (1).
The prevalence of EBV in the general population is very 
high, and there are nearly 200,000 new cases of infec-
tion in the world every year. In the first two decades 
of life EBV infects 90% of all individuals. According 
to Ueda et al., EBV is a reversible latent infection in B 
cells (2).
It is believed that EBV initially penetrates and multi-
plies within epithelial cells, followed by release into sa-
liva, affecting B lymphocytes and spreading throughout 
the rest of the body. However, most affected individuals 
are asymptomatic, despite detection of the virus in dif-
ferent body secretions and blood (3). 
Saliva plays a significant role in the capacity of EBV to 
become transmitted to other people. The virus is infec-
tive when present in saliva, both in asymptomatic and 
symptomatic carriers. EBV is released into saliva from 
the epithelial cells, and it is in this fluid where maxi-
mum infectious capacity is observed (1). On the other 
hand, EBV is found not only in B cells but also in na-
sopharyngeal carcinomas (4).
Salivary EBV has been analyzed in several oral diseas-
es, particularly in patients with periodontal problems 
(5-9). In 2007 we already addressed the presence of EBV 
in potentially malignant disorders (PMD) and in oral 
squamous cell carcinoma (OSCC), though involving a 
smaller number of cases (10). However, there have been 
recent controversial findings in the literature regarding 
the association between EBV and OSCC. The present 
study analyzes the frequency of EBV DNA positivity in 
OSCC and PMD comparing with controls. 
Material and Methods
Three groups were studied: Group 1 (12 OSCC), Group 
2 (12 PMD) and Group 3 (47 healthy controls).
There were no clinical differences among the three 
groups regarding age or gender (p>0.05). 
Oral squamous cell carcinoma was diagnosed from an 
incisional biopsy. In the leukoplakia group (Group 2) we 
also obtained a biopsy to establish the diagnosis follow-
ing the criteria of Carrard et al. (11).
The study was approved by the Ethics Committee of the 
University of Valencia (Spain), and informed consent 
was obtained from each patient. 
Whole non-stimulated saliva was obtained in all cases 
according to the criteria of Navacek et al. (12). Saliva 
samples were immediately stored and frozen at -80º un-
til EBV DNA analysis.
EBV DNA salivary analysis was performed by PCR 
following the methodology described elsewhere (3). 
Saliva samples were obtained and DNA was extracted 
as reported (2). EBV DNA levels were determined by 
qualitative real-time PCR (qPCR) targeting the EBV 
Gen LMP1 region.
The present case-control study evaluated the presence 
and percentage of positive findings regarding EBV 
DNA and analyzed the association of the virus to the 
different groups using the χ2 test. Statistical signifi-
cance was considered for p < 0.05. 
Results
The highest percentage of positive salivary EBV DNA 
corresponded to the OSCC group, followed by the leu-
koplakia (PMD) group and the controls (Table 1). The 
differences between groups were not statistically sig-
nificant, however (p>0.05) (Table 2).
Four of the 9 cases of proliferative verrucous leukopla-
kia (44.4%) presented positive salivary EBV DNA. In 
those cases with only homogeneous leukoplastic areas, 
the positivity rate was lower (33.3%).
 
Discussion
Epstein-Barr virus is very common in normal indivi-
duals of the general population. According to Ueda et 
al. (2), its prevalence may reach 90% in saliva. The 
virus can penetrate and multiply within the epithelial 
cells, followed by release into saliva.
The salivary EBV DNA detection rate and consequently 
shedding of the virus in healthy persons ranges from 
22-90% (3). Despite the variability among authors, the 
detection rate is usually high in healthy controls. In this 
respect we found 40.4% of our controls to be positive 
for DNA EBV.
Epstein-Barr virus DNA in saliva has been analyzed in 
several diseases such as connective tissue disorders (13), 
adverse drug reactions with eosinophilia and systemic 
symptoms (DRESS) (14), periimplantitis (15), HIV in-
fection (3,16), periodontal disease (6) and in transplant 
patients (17).
In cancer patients, EBV in saliva has been described 
as a useful tool in nasopharyngeal carcinomas. In ad-
vances disease stages the EBV DNA levels are higher 
than in early stages (18).
Epstein-Barr virus has also been studied in OSCC pa-
tients, though the results are controversial. According 
to some investigators, EBV is associated to OSCC and 
this association seems to be enhanced by betel quid 
chewing, thus suggesting that EBV may be an impor-
tant etiological risk factor for OSCC (19). Furthermore, 
Jiang et al. (20) described a high prevalence of human 
papillomavirus (HPV)/EBV infection and coinfection 
in non-cancerous base of tongue (BOT) lesions and 
tonsil malignancies, possibly reflecting their origins in 
lymphoid-rich tissue (20). 
In contrast, other authors have found no significant 
OSCC risk in subjects with EBV infection (21,22). Like-
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Case Group Age Gender Type of lesion EBV + DNA 
1 Cancer 60 2 Ulceration - 
2 Cancer 77 1 Ulceration - 
3 Cancer 79 1 Ulceration + 
4 Cancer 60 2 Ulceration + 
5 Cancer 69 2 Ulceration + 
6 Cancer 61 1 Ulceration - 
7 Cancer 73 1 Ulceration + 
8 Cancer 80 2 Ulceration + 
9 Cancer 88 1 Ulceration + 
10 Cancer 84 1 Ulceration - 
11 Cancer 75 2 Ulceration + 
12 Cancer 51 2 Ulceration - 
13 PMD 55 1 Verrucous leukoplakia - 
14 PMD 74 1 Verrucous leukoplakia - 
15 PMD 86 1 Verrucous leukoplakia + 
16 PMD 82 1 Verrucous leukoplakia - 
17 PMD 67 1 Verrucous leukoplakia + 
18 PMD 76 1 Verrucous leukoplakia - 
19 PMD 63 1 Verrucous leukoplakia + 
20 PMD 62 2 Verrucous leukoplakia + 
21 PMD 80 1 Verrucous leukoplakia - 
22 PMD 69 2 Homogeneous leukoplakia - 
23 PMD 48 1 Homogeneous leukoplakia + 
24 PMD 56 1 Homogeneous leukoplakia - 
25 Control 58 2 No lesions - 
26 Control 48 1 No lesions - 
27 Control 71 1 No lesions - 
28 Control 74 2 No lesions - 
29 Control 43 2 No lesions + 
30 Control 68 1 No lesions - 
31 Control 77 2 No lesions - 
32 Control 73 1 No lesions + 
33 Control 57 2 No lesions - 
34 Control 50 2 No lesions - 
35 Control 49 2 No lesions - 
36 Control 58 2 No lesions + 
37 Control 47 1 No lesions - 
38 Control 75 1 No lesions + 
39 Control 46 1 No lesions + 
40 Control 76 2 No lesions - 
41 Control 50 1 No lesions + 
42 Control 54 2 No lesions + 
43 Control 48 1 No lesions - 
44 Control 53 1 No lesions + 
45 Control 63 1 No lesions - 
46 Control 46 1 No lesions - 
47 Control 81 2 No lesions - 
48 Control 65 1 No lesions + 
49 Control 30 2 No lesions - 
50 Control 28 2 No lesions + 
51 Control 75 1 No lesions + 
52 Control 70 1 No lesions + 
53 Control 25 2 No lesions + 
54 Control 28 2 No lesions + 
55 Control 22 1 No lesions - 
56 Control 80 2 No lesions + 
57 Control 27 2 No lesions + 
58 Control 35 1 No lesions - 
59 Control 46 1 No lesions - 
60 Control 22 1 No lesions - 
61 Control 42 1 No lesions - 
62 Control 25 1 No lesions + 
63 Control 29 1 No lesions - 
64 Control 37 2 No lesions - 
65 Control 34 1 No lesions - 
66 Control 19 2 No lesions - 
67 Control 56 2 No lesions - 
68 Control 36 2 No lesions - 
69 Control 53 2 No lesions - 
70 Control 35 2 No lesions + 
71 Control 50 2 No lesions + 
Table 1. Epstein-Barr virus DNA findings among the three groups.
PMD: Potentially malignant disorder
Gender: 1 Female, 2 Male
Cancer: Group 1
PMD: Group 2
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wise, the data published in 2014 by Saravani et al. (23) 
neither supported the hypothesis that EBV and HHV-6 
are directly involved in OSCC nor ruled out the possi-
bility that these viruses might play an indirect carcino-
genic role in this area. 
Considering the above discrepancies, we tried to analyze 
the presence of EBV DNA in the saliva of patients with 
potentially malignant disorders and oral squamous cell 
carcinoma. No significant differences were observed 
among OSCC, PMD and the controls (p>0.05). Howev-
er, EBV DNA positivity was greater in the OSCC group 
than in the PMD group or controls (Table 2). Studies 
with a larger number of cases are required to determine 
whether such higher percentage EBV DNA positivity in 
OSCC is also found in other larger populations. 
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 Value Significance 
Chi square of Pearson 1.270 0.530 
 
 Saliva DNA Epstein-Barr virus  Negative Positive Total 
Groups 
Controls 28 (59.6%) 19 (40.4%) 47 
OSCC 5 (41.7%) 7 (58.3%) 12 
PMD 7 (58.3%) 5 (41.7%) 12 
Table 2. Summary of DNA EBV detection in saliva of the three groups.
OSCC: Group 1.
PMD: Group 2.
